AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Eagle Global Advisors LLC

Eagle Global Advisors LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,385 shares of the company’s stock after selling 1,115 shares during the period. Eagle Global Advisors LLC’s holdings in AstraZeneca were worth $2,720,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Anchor Investment Management LLC acquired a new position in shares of AstraZeneca during the fourth quarter valued at approximately $26,000. Compagnie Lombard Odier SCmA purchased a new position in AstraZeneca in the fourth quarter valued at about $27,000. Nemes Rush Group LLC increased its holdings in AstraZeneca by 375.6% in the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock worth $29,000 after buying an additional 338 shares during the last quarter. Northwest Financial Advisors acquired a new position in shares of AstraZeneca during the 4th quarter worth $34,000. Finally, Atlantic Edge Private Wealth Management LLC bought a new position in AstraZeneca during the fourth quarter valued at about $35,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Up 0.5 %

NASDAQ AZN traded up $0.36 during trading hours on Friday, hitting $78.54. 3,566,580 shares of the company traded hands, compared to its average volume of 5,299,819. The stock has a market capitalization of $243.51 billion, a price-to-earnings ratio of 38.50, a P/E/G ratio of 1.40 and a beta of 0.47. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $79.36. The business’s 50-day moving average is $71.80 and its 200-day moving average is $67.74. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.95 by $0.08. The business had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. Sell-side analysts anticipate that AstraZeneca PLC will post 4.04 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on AZN. BMO Capital Markets upped their price target on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $81.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.